KALA BIO (KALA) Competitors $5.28 +0.18 (+3.53%) Closing price 07/7/2025 04:00 PM EasternExtended Trading$5.56 +0.29 (+5.40%) As of 08:33 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock KALA vs. FATE, PLX, NKTX, CRBU, ACTU, CRDL, ATOS, KRRO, VXRT, and GNLXShould you be buying KALA BIO stock or one of its competitors? The main competitors of KALA BIO include Fate Therapeutics (FATE), Protalix BioTherapeutics (PLX), Nkarta (NKTX), Caribou Biosciences (CRBU), Actuate Therapeutics (ACTU), Cardiol Therapeutics (CRDL), Atossa Genetics (ATOS), Korro Bio (KRRO), Vaxart (VXRT), and Genelux (GNLX). These companies are all part of the "pharmaceutical products" industry. KALA BIO vs. Its Competitors Fate Therapeutics Protalix BioTherapeutics Nkarta Caribou Biosciences Actuate Therapeutics Cardiol Therapeutics Atossa Genetics Korro Bio Vaxart Genelux Fate Therapeutics (NASDAQ:FATE) and KALA BIO (NASDAQ:KALA) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, earnings, valuation, dividends, profitability and media sentiment. Which has more risk and volatility, FATE or KALA? Fate Therapeutics has a beta of 2.18, indicating that its share price is 118% more volatile than the S&P 500. Comparatively, KALA BIO has a beta of -1.88, indicating that its share price is 288% less volatile than the S&P 500. Is FATE or KALA more profitable? KALA BIO has a net margin of 0.00% compared to Fate Therapeutics' net margin of -1,318.93%. Fate Therapeutics' return on equity of -47.17% beat KALA BIO's return on equity.Company Net Margins Return on Equity Return on Assets Fate Therapeutics-1,318.93% -47.17% -34.60% KALA BIO N/A -369.29%-64.99% Which has preferable earnings & valuation, FATE or KALA? KALA BIO has lower revenue, but higher earnings than Fate Therapeutics. Fate Therapeutics is trading at a lower price-to-earnings ratio than KALA BIO, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioFate Therapeutics$13.63M8.91-$186.26M-$1.49-0.71KALA BIO$3.89M8.75-$38.51M-$8.24-0.64 Do insiders and institutionals believe in FATE or KALA? 97.5% of Fate Therapeutics shares are held by institutional investors. Comparatively, 24.6% of KALA BIO shares are held by institutional investors. 5.5% of Fate Therapeutics shares are held by company insiders. Comparatively, 8.3% of KALA BIO shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Does the media prefer FATE or KALA? In the previous week, Fate Therapeutics had 6 more articles in the media than KALA BIO. MarketBeat recorded 7 mentions for Fate Therapeutics and 1 mentions for KALA BIO. Fate Therapeutics' average media sentiment score of 0.72 beat KALA BIO's score of 0.00 indicating that Fate Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Fate Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive KALA BIO 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts prefer FATE or KALA? Fate Therapeutics presently has a consensus price target of $3.83, suggesting a potential upside of 261.64%. KALA BIO has a consensus price target of $13.50, suggesting a potential upside of 155.68%. Given Fate Therapeutics' higher probable upside, equities analysts clearly believe Fate Therapeutics is more favorable than KALA BIO.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Fate Therapeutics 0 Sell rating(s) 7 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.13KALA BIO 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryFate Therapeutics beats KALA BIO on 10 of the 16 factors compared between the two stocks. Get KALA BIO News Delivered to You Automatically Sign up to receive the latest news and ratings for KALA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding KALA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KALA vs. The Competition Export to ExcelMetricKALA BIOMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$32.91M$2.91B$5.52B$9.02BDividend YieldN/A2.44%5.24%4.05%P/E Ratio-0.6420.4427.2520.08Price / Sales8.75190.25371.3293.25Price / CashN/A41.7026.2128.59Price / Book2.617.397.945.55Net Income-$38.51M-$55.04M$3.17B$248.49M7 Day Performance9.09%2.51%1.79%4.87%1 Month Performance27.54%-0.21%1.27%6.63%1 Year Performance-22.47%3.41%33.57%20.38% KALA BIO Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KALAKALA BIO3.3526 of 5 stars$5.28+3.5%$13.50+155.7%-23.5%$32.91M$3.89M-0.6430FATEFate Therapeutics4.2508 of 5 stars$1.12+7.7%$3.83+242.3%-66.6%$119.19M$13.63M-0.75550Gap UpPLXProtalix BioTherapeutics2.757 of 5 stars$1.48-3.9%$15.00+913.5%+40.0%$117.82M$59.76M-11.38200NKTXNkarta2.0809 of 5 stars$1.66flat$14.33+763.5%-67.4%$117.79MN/A-1.10140CRBUCaribou Biosciences2.0555 of 5 stars$1.26flat$8.50+574.6%-13.1%$117.19M$9.99M-0.78100Analyst UpgradeACTUActuate Therapeutics2.8314 of 5 stars$6.11+2.5%$20.50+235.5%N/A$116.93MN/A0.0010Positive NewsHigh Trading VolumeCRDLCardiol Therapeutics1.894 of 5 stars$1.36-3.5%$8.00+488.2%-26.8%$116.54MN/A-4.0020Upcoming EarningsATOSAtossa Genetics1.5853 of 5 stars$0.83-5.6%$6.17+643.0%-22.4%$113.61MN/A-3.958KRROKorro Bio1.7013 of 5 stars$12.49+3.8%$102.43+720.1%-65.6%$112.97M$2.27M-1.3270VXRTVaxart2.2392 of 5 stars$0.45-8.6%$3.00+563.7%-51.4%$112.90M$28.70M-1.67120Gap DownGNLXGenelux1.9638 of 5 stars$2.87-4.0%$17.75+518.5%+46.5%$112.83M$10K-3.2610News CoverageGap Down Related Companies and Tools Related Companies Fate Therapeutics Competitors Protalix BioTherapeutics Competitors Nkarta Competitors Caribou Biosciences Competitors Actuate Therapeutics Competitors Cardiol Therapeutics Competitors Atossa Genetics Competitors Korro Bio Competitors Vaxart Competitors Genelux Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KALA) was last updated on 7/8/2025 by MarketBeat.com Staff From Our PartnersEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredF1 Engineering Powers This Electric Marine MotorThe future of marine propulsion has arrived - powered by F-1 grade engineering. In collaboration with McLar...The Tomorrow Investor | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding KALA BIO, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share KALA BIO With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
